<code id='1C6A6F030E'></code><style id='1C6A6F030E'></style>
    • <acronym id='1C6A6F030E'></acronym>
      <center id='1C6A6F030E'><center id='1C6A6F030E'><tfoot id='1C6A6F030E'></tfoot></center><abbr id='1C6A6F030E'><dir id='1C6A6F030E'><tfoot id='1C6A6F030E'></tfoot><noframes id='1C6A6F030E'>

    • <optgroup id='1C6A6F030E'><strike id='1C6A6F030E'><sup id='1C6A6F030E'></sup></strike><code id='1C6A6F030E'></code></optgroup>
        1. <b id='1C6A6F030E'><label id='1C6A6F030E'><select id='1C6A6F030E'><dt id='1C6A6F030E'><span id='1C6A6F030E'></span></dt></select></label></b><u id='1C6A6F030E'></u>
          <i id='1C6A6F030E'><strike id='1C6A6F030E'><tt id='1C6A6F030E'><pre id='1C6A6F030E'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:16
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          JPM: CVS says Medicare Advantage patients are impacting profits

          WilfredoLee/APMedicareAdvantagememberscontinuetogotothedoctorandgethealthcareproceduresalotmorethanp